Obesity has increased in prevalence worldwide, which is thought to be due to the influences of an obesity-promoting environment and genetic factors. Despite these influences there are individuals and animals that resist obesity. Spontaneous physical activity (SPA), which generates nonexercise activity thermogenesis (NEAT), can reduce weight gain. Injections of hypothalamic neuropeptide orexin A (OxA) into the lateral rostral hypothalamus (rLH) increased levels of SPA and increase obesity resistance. The neurological mechanism that drive SPA are not fully defined. Understanding the mechanism(s) by which NEAT is regulated will have the potential to develop novel approaches to preventing and treating obesity. OxA has been shown to activate extracellular signal-regulated kinases 1/2 (ERK1/2) and p38 mitogen activated phosphate kinase (MAPK) in various cell models. Mice globally lacking the inhibitor for both these kinases, MKP-1, have been reported to be obesity resistant due in part to an increase in energy expenditure and SPA, but it is unknown whether OxA signaling is altered. OxA has also been recently shown to increase ATP and the transcription factor hypoxia inducible factor-1a (HIF-1a) in hypothalamic tissue under normoxic conditions. This is noteworthy given that HIF-1a increases oxidative phosphorylation. Additional independent studies have shown that HIF-1a expression is regulated in part by MAPKs and the transcriptional coactivator PGC-1a. PGC-1a is a regulator of mitochondrial biogenesis, can simultaneously upregulate genes that protect against oxidative stress, and increases ATP production. The central hypothesis proposed in this application is: SPA effects on weight gain depend in part on OxA signaling in the rLH, which alters genes and proteins involved in short- and long-term intracellular metabolic function. The three specific aims that will test this hypothesis are: 1) Determine in vitro if OxA increases HIF-1? by the activation of ERK1/2 and p38 MAPKs. 2) Test in vitro whether OxA-induced activation of HIF-1? mediates intracellular metabolic changes in rat rLH sections. 3) Evaluate in vivo if OxA treatment ameliorates or prevents changes in the ERK1/2-p38-MAPK-HIF-1?- PGC-1? pathway and intracellular metabolic responsiveness in the rLH following the development of diet-induced obesity. The immediate goal of the work proposed will characterize cellular mechanisms important in OxA-induced SPA using in vitro and in vivo models, with a long-term goal of developing therapeutic treatments for obesity through pharmacological manipulation of these identified pathways. The expected outcome is that OxA will increase the short- and long-term intracellular metabolic capacity of activated neurons, resulting in the maintenance of elevated SPA and obesity resistance. This will impact the field of obesity research by identifying a mechanism through which intracellular OxA signaling might contribute to obesity resistance. The innovation and the challenge to current paradigms are that the proposed studies suggest a new mechanism through which OxA elevates SPA, which is by altering genes that increase intracellular metabolic resistance in activated rLH neurons. This mechanism may be responsible for conferring long-term obesity resistance and would provide a new therapeutic target for obesity.
Completion of the research goals outlined in this proposal would lead to a greater understanding of neuroregulatory mechanisms of physical activity by providing novel anti-obesity therapeutic targets. Obesity and its associated health problems have a significant economic impact on the U.S. health care system. Veterans that use the VA health care system as their primary source of care are significantly more likely to be overweight or obese than either the general population or veterans in other health care systems. Interventions which reduce the prevalence of obesity will thus translate into direct cost savings for the VA as a whole. Improving weight management care by evaluating the central nervous system's regulation of physical activity will additionally benefit disabled populations of veterans who have increased risk of obesity or are obese due to their limited mobility. The reduction of obesity morbidities and mortalities will not only reduce medical costs for the VA but will improve the wellbeing of all veterans served by the VA.
|Duffy, Cayla M; Xu, Hongliang; Nixon, Joshua P et al. (2017) Identification of a fatty acid binding protein4-UCP2 axis regulating microglial mediated neuroinflammation. Mol Cell Neurosci 80:52-57|
|Mavanji, Vijayakumar; Butterick, Tammy A; Duffy, Cayla M et al. (2017) Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice. Neurobiol Learn Mem 146:21-30|
|Duffy, Cayla M; Nixon, Joshua P; Butterick, Tammy A (2016) Orexin A attenuates palmitic acid-induced hypothalamic cell death. Mol Cell Neurosci 75:93-100|
|Gac, L; Butterick, T A; Duffy, C M et al. (2016) Role of the non-opioid dynorphin peptide des-Tyr-dynorphin (DYN-A(2-17)) in food intake and physical activity, and its interaction with orexin-A. Peptides 76:14-8|
|Holley, Christopher T; Long, Eric K; Butterick, Tammy A et al. (2015) Mitochondrial fusion proteins in revascularized hibernating hearts. J Surg Res 195:29-36|
|Holley, Christopher T; Duffy, Cayla M; Butterick, Tammy A et al. (2015) Expression of uncoupling protein-2 remains increased within hibernating myocardium despite successful coronary artery bypass grafting at 4 wk post-revascularization. J Surg Res 193:15-21|
|Duffy, Cayla M; Yuan, Ce; Wisdorf, Lauren E et al. (2015) Role of orexin A signaling in dietary palmitic acid-activated microglial cells. Neurosci Lett 606:140-4|
|Butterick, Tammy A; Duffy, Cayla M; Lee, Rachel E et al. (2014) Use of a caspase multiplexing assay to determine apoptosis in a hypothalamic cell model. J Vis Exp :|
|Butterick, Tammy A; Billington, Charles J; Kotz, Catherine M et al. (2013) Orexin: pathways to obesity resistance? Rev Endocr Metab Disord 14:357-64|
|Cabrera, Jesús A; Butterick, Tammy A; Long, Eric K et al. (2013) Reduced expression of mitochondrial electron transport chain proteins from hibernating hearts relative to ischemic preconditioned hearts in the second window of protection. J Mol Cell Cardiol 60:90-6|